glp-1 receptor agonist bcbs weight loss drug demand surges in Alabama glp-1 receptor agonist bcbs Schematic

Payers and clinicians alike are beginning to treat obesity as a primary, chronic condition rather than a comorbidity, signaling a major shift in market dynamics

Glucagon-like peptide1 (GLP1) receptor agonists represent a powerful treatment option to aid in managing these complex conditions

Promising OS and PFS data have been shown, especially in non-squamous taxane-nave NSCLC (n=42), with a median PFS of 6.4 months (95% CI, 4.5 to 10.5) and median OS of 16.3 months (95% CI, 11.5 to NR), compared to 3.5 months (95% CI, 2.7 to 5.3) and 11.2 months (95% CI, 8.3 to 13.7), respectively, in all NSCLC subtypes [87]

PMID 12632346